Cambridge, MA30+ days ago
Its lead asset, zolucatetide (FOG-001), is a first-in-class, clinically validated direct inhibitor of the interaction between -catenin and the T-cell factor (TCF) family of transcription factors, implicated in millions of cancer cases annually, including in colorectal cancer, desmoid tumors, hepatocellular carcinoma and a range of other Wnt/-catenin-driven tumors. Develop, implement, and clearly communicate integrated synthesis strategies in partnership with Design, Data Science, De Novo Discovery, Molecular & Cellular Biology, DMPK, and Pharmacology teams to achieve hit-to-lead and lead optimization milestones.